Home>>Signaling Pathways>> Others>>Anticonvulsant agent 1

Anticonvulsant agent 1 (Synonyms: 4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide)

Catalog No.GC33745

Anticonvulsant agent 1 is an anticonvulsant agent extracted from patent WO2001062726A2, Compound 156.

Products are for research use only. Not for human use. We do not sell to patients.

Anticonvulsant agent 1 Chemical Structure

Cas No.: 357336-17-5

Size Price Stock Qty
1mg
$937.00
In stock
5mg
$1,866.00
In stock
10mg
$3,171.00
In stock
20mg
$5,598.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Anticonvulsant agent 1 is an anticonvulsant agent extracted from patent WO2001062726A2, Compound 156.

The inhibition constant (Ki) of Anticonvulsant agent 1 (Compound 156) is determined in competitive binding experiments by measuring the binding of a single concentration of a radioactive ligand at equilibrium with various concentrations of the unlabeled test substance. The concentration of the test substance inhibiting 50 % of the specific binding of the radioligand is called the IC50. The equilibrium dissociation constant Ki is proportional to the IC50 and is calculated. Anticonvulsant agent 1 shows pKi values of 6.0 and greater[1]

[1]. Differding, Edmond, et al. 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES. WO2001062726A2

Reviews

Review for Anticonvulsant agent 1

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Anticonvulsant agent 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.